Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Biologic therapy. Massachusetts General Hospital Cancer Center, Boston, MA, United States

Survival: 17.5 months
Toxicity Grade: 3
Treatments: Biologic therapy
Country: United States
City/State/Province: Boston, MA
Hospital: Massachusetts General Hospital Cancer Center
Journal: Link
Date: 5/2008

Patients: This phase II study involved 31 patients with advanced non-small-cell lung cancer. These patients also had a mutation in a gene called EGFR. The median age was 62, ranging from 26 to 88 years of age. The majority of patients (61%) were female.

Treatment: Patients were treated with the biological therapy gefitinib.

Toxicity: Grade 3 pneumonitis was the most serious toxicity reported. Grade 3 nausea/vomiting, anorexia, and abnormal liver function tests were also reported. Grade 1 and 2 toxicities included rash, diarrhea, fatigue, stomatitis, and weight changes, and headache.

Results: The median overall survival was 17.5 months.

Support: This study was supported by research funds from AstraZeneca, which markets gefitinib as Iressa“.

Correspondence: Dr. Lecia V. Sequist

E-mail to a Friend Email Physician More Information